Kornimate/medical-research-clean huggingface dataset:
can urinary partial oxygen pressure be an indicator of acute kidney injury in patients with sepsis?

Conditions: Acute Kidney Injury; Sepsis

Summary: the ability of bladder urinary partial pressure, measured as a reflection of renal medullary oxygen tension, which is an indicator of the development of acute kidney injury (aki), to predict the development of aki at an early stage.

patients hospitalised in the intensive care unit with a diagnosis of sepsis will be followed up for the development of abh. this follow-up will be performed for 5 days after hospitalisation. during this period, patients will be sampled for ngal 5 times in total, once every day. puo2 will be sampled daily to determine puo2 and to observe the development of aki, and in cases of hypotension where the mean arterial pressure falls below 65 mmhg or in cases of severe acidosis, extra will be sampled at least 5 times, once every day. puo2 will be analysed in the blood gas device and puo2 value will be recorded. for ngal analysis, patient blood will be collected in etda tubes and stored at -80 °c until analysis. ngal will then be measured by turbidimetric imminoassay method. the comorbidities of the patients will be questioned and recorded, the types and amounts of fluids taken, whether they received blood and blood products, and if so, which product and how much they received will be recorded. apachi ii score and sofa scores of the patients at hospitalisation will be recorded. gcs, whether mechanical ventilation support is provided or not, if any, ventilation method, mode and ventilation parameters will be recorded. in addition to these, mean arterial pressure, pulse, temperature, spo2, fio2 values will be recorded clinically. haemoglobin, haemotocrit, platelets, bun, creatinine, biluribins, liver function tests and arterial blood gas will be recorded in the laboratory. in addition, whether the patients have ards, whether they are receiving renal replacement therapy and if so, the prescription and ultrasonography findings will be recorded.

Eligibility criteria:
inclusion criteria: * patients admitted to intensive care unit with sepsis exclusion criteria: * causing an infection other than sepsis at the time of admission * acute renal failure at the time of admission * having a creatinine value above 1.5 mg/dl at the time of admission * previously known chronic renal failure or being on a routine dialysis programme (receiving renal replacement therapy) * having one kidney * having another known kidney disease

Keywords: acute kidney injrury, sepsis, urine parcial oxygen pressure
efficacy and safety of protein product in volunteers with sarcopenia

Conditions: Sarcopenia

Summary: the objective of this study are to evaluate efficacy and safety of protein product in volunteers with sarcopenia.

there are 45 patients in this study. they are randomly divided into 3 groups which are whey protein isolate group, isolated soy protein group, placebo group. they will take the sample 1 sachet/day for 12 weeks. muscle strength, muscle mass, physical performance, sarcopenia score, body weight, body mass index, protein, immunoglobulins, quality of life, liver function, kidney function, other laboratory value, and adverse effects are evaluated.

Eligibility criteria:
inclusion criteria: * age more than 20 years * sarcopenia score more than 4 * handgrip strength less than 28 kg in male and less than 18 kg in female and muscle mass less than 7 kg/m2 in male and less than 5.7 kg/m2 in female or gait speed (6-meter walk) less than 1 m/s * can take protein from animal * can read and write or have people to look after * willing to participate in this study exclusion criteria: * allergic to protein from animals and plants * hepatitis or cirrhosis * glomerular disease or glomerular filtration rate less than 60 ml/min/1.73m2 * cancer or heart disease * cannot walk * pregnancy and lactation * duodenal surgery * take protein supplement within 2 weeks * take protein in normal food more than 1.2 g/body weight/day * participating in other studies
snow physical properties and human ventilatory response

Conditions: Hypoxic Respiratory Failure; Hypercapnic Respiratory Failure; Avalanche Burial; Snow Physical Properties

Summary: sufficient oxygenation is critical for completely buried avalanche victims to avoid life-threatening consequences during hypoxic exposure. snow contains a remarkable capacity to maintain air availability; it was suspected that the snow physical properties affect the development of hypoxia and hypercapnia. the aim of this study was to evaluate the influence of different snow physical properties on the development of hypoxia and hypercapnia in subjects breathing into an artificial air pocket in snow. twelve male healthy subjects breathed through an airtight face-mask and 40cm tube into an artificial air pocket of 4l. every subject performed three tests on different days with varying snow characteristics. symptoms, gas and cardiovascular parameters were monitored up to 30min. tests were interrupted at spo2 \<75% (primary endpoint); or due to subjective symptoms like dyspnea, dizziness, and headache (i.e. related to hypercapnia). snow density was assessed via standard methods and micro-computed tomography (ct) analysis, and permeability and penetration with the snow micro-penetrometer (smp).


Eligibility criteria:
inclusion criteria: * healthy volunteers with an age above 18yr-old, physically active. * volunteers have been informed and have signed consent. exclusion criteria: * lack of consent. * chronic previous illness of the respiratory tract or of the cardiovascular system. * acute disease at or immediately prior to the test (eg, flu-like infection, fever of unknown origin). * eurac employees.
anesthetic to reduce dysphagia after anterior cervical discectomy and fusion surgery

Conditions: Dysphagia

Summary: the main objective of this study is to analyze the effects of local anesthetic application into the retropharyngeal space and its ability to reduce dysphagia symptoms and/or occurrence rates in patients undergoing anterior cervical discectomy and fusion.

the patients will be randomly assigned into one of the two groups to receive either bupivacaine hydrochloride 0.5% solution if they are randomized to the treatment group or 0.9% nacl solution if they are randomized to the control group. these solutions will be poured into the retropharyngeal space intraoperatively before wound closure.

Eligibility criteria:
inclusion criteria: * patients older than 18 y.o. * patients undergoing one- or two-level anterior cervical discectomy and fusion surgery for radiculopathy or myelopathy symptoms * patients are wiling and able to sign informed consent and complete questionnaires exclusion criteria: * more than 2-level acdf surgeries * previous cervical spine surgery * surgeries for trauma, infection or tumor * known hypersensitivity reactions to bupivacaine hydrochloride or other amino-amide anesthetics (e.g. lidocaine) * known history of swallowing issues (e.g. dysphagia, odynophagia) * pregnant or breastfeeding

Keywords: anterior cervical discectomy and fusion dysphagia
development of clinical evidence for optimal management of adrenal diseases based on real-world data

Conditions: Adrenal Tumor; Primary Aldosteronism; Cushing Syndrome; Pheochromocytoma; Adrenal Cortical Carcinoma

Summary: this research aims to establish clinical evidence for optimal treatment guidelines for adrenal diseases using real-world data. the approach involves building prospective and retrospective patient registries, which will be utilized to develop and conduct research on disease-specific protocols for adrenal disorders. the study targets patients with primary aldosteronism, pheochromocytoma, adrenal cancer, adrenal incidentalomas, and mild autonomous cortisol secretion. registries for patients with adrenal diseases will be obtained from seoul national university hospital and asan medical center, along with securing a common data model. the ultimate goal is to conduct research to generate clinical evidence for adrenal diseases using these resources.

the ultimate goal is to develop clinical evidence for unmet needs in adrenal gland diseases using real-world data, thereby contributing to the optimization of treatment guidelines. this involves: 1. generating real-world healthcare data through prospective and retrospective registries specific to each adrenal disease. 2. acquiring a common data model for adrenal diseases, applicable across both domestic and international multicenter settings. 3. creating real-world data linked with hospital medical records and public data for each adrenal disease, utilizing anonymized information merging services. 4. developing and conducting research based on prospective and retrospective registries, a common data model, and the utilization of public-medical data for different adrenal diseases. study design: prospective and retrospective patient registries. study population: patients with adrenal gland disorders, including primary aldosteronism, pheochromocytoma, adrenal cancer, adrenal incidentalomas, and mild autonomous cortisol secretion research methods: 1. securing prospective and retrospective registries of patients with adrenal diseases. 2. obtaining a common data model for adrenal diseases. 3. utilizing the secured registries and common data model for multicenter studies to generate clinical evidence for adrenal diseases. 4. linking public and medical data with the secured registries to further research in generating clinical evidence for adrenal diseases.

Eligibility criteria:
inclusion criteria: * patients with adrenal diseases such as adrenal cortical carcinoma, cushing's syndrome, primary aldosteronism, pheochromocytoma, adrenal incidentaloma * patients who are 19 years or older exclusion criteria: * patients younger than 19 years old
the role of tlr-4 polymorphisms in children with urinary track infections

Conditions: Urinary Tract Infection

Summary: purpose so far anatomical abnormalities (mostly congenital) were, in the majority of the patients, associated with urinary track infections. in this study the researchers will try to investigate the role of tlrs as molecular interactions between bacterial virulence and host response. tlrs are important mediators in the development of the natural immunity against bacteria. they recognize microbial pathogen associated molecular patterns and alert the host's immune system to the presence of invading microbes

the aim of his observational case-control study is to : 1. investigate if the expression of tlr2 and tlr4 mediate in the development of the natural immunity of the uroepithileal cells against bacteria. 2. evaluate the effect of the tlr-gene asp299gly and thr399ile polymorphisms on the development and clinical severity of urinary tract infections (uti) in children. 3. determine the association of the expression of tlr-2 and tlr-4 and tlr-4 polymorphisms with the formation of renal scar in children. 4. investigate the expression of tlr-2 and tlr-4 and tlr-4 polymorphisms in healthy children and elaborate the results to the possible carriers of these polymorphisms.

Eligibility criteria:
inclusion criteria: * for the patients * 6months -14 years of age * unrelated male and female children with one episode of acute urinary track infection (positive urine culture and clinical symptoms ) * with/without anatomic genitourinary anomalies . * children with upper uti or children with lower uti * sign written informed consent inclusion criteria: for the controls * 6 months-14 years of age * age and gender matched with the patients * unrelated male and female children with no recorded history of urinary track infection and negative urine cultures . * sign written informed consent exclusion criteria: * for the patients * subjects who do not meet the criteria above * severe or chronic illness * symptoms of acute infection * immune deficiency or immune suppressor therapy * medication exclusion criteria: for the controls * subjects who do not meet the criteria above * severe or chronic illness * symptoms of acute infection * immune deficiency or immune suppressor therapy * medication

Keywords: toll like receptors tlr 4 urinary track infections in children tlr 4 polymorphisms innate immunity defence mechanisms immune responses
validation of non-invasive miniature optical sensors for scoring sleep stages

Conditions: Sleep-Wake Disorders; Healthy

Summary: validation of two devices with optical sensor in healthy participants and patients with sleep wake disorders.

the objective of this study is to evaluate and optimize a method of detecting sleep and sleep stages based on a new algorithm combining actigraphy and heart rate variability (measured by optical analysis of the pulse wave) to determine sleep architecture (segmented into three phases: wake, rem and nrem) with high accuracy compared to the gold standard polysomnography.

Eligibility criteria:
patients with sleep wake disorders inclusion criteria: * 18 ≤ age ≤ 80 years * suspected sleep wake disorder (sleep apnea, sleep movement disorders, hypersomnia, parasomnia) * written informed consent exclusion criteria: * skin condition with eczema or damaged skin * ischemia (cutaneous) * allergy against nickel * allergy against silicone * current treatment with vasoactive drugs (e.g. beta-blockers, calcium channel antagonists, nitroglycerin, etc.) and/or antidepressive drugs (e.g. serotonin reuptake inhibitors, etc.). * known infection with multiresistant bacteria * implanted devices (e.g. pacemaker, pumps) * rhythmogenic heart disease (e.g. resting heart rate \> 120/min) * severe or untreated arterial hypertension (blood pressure \> 140mmhg systolic, \>90mmhg diastolic) * hypotension (blood pressure \< 90mmhg systolic, \< 60 mmhg diastolic) * current alcohol or drug abuse, alcohol consumption the same day as the study * consumption of coffee 7h before * dark skin pigmentation * severe metabolic disease (e.g. diabetes) * pregnancy or lactation * physical handicap effecting the two arms * wound in the wrist region * too large or too small wrist healthy subjects inclusion criteria: * 18 ≤ age ≤ 80 years * written informed consent exclusion criteria: * skin condition with eczema or damaged skin * ischemia (cutaneous) * allergy against nickel * allergy against silicone * any medication (except birth control pill) * known infection with multiresistant bacteria * implanted devices (e.g. pacemaker, pumps) * rhythmogenic heart disease (e.g. resting heart rate \> 120/min) * severe or untreated arterial hypertension (blood pressure \> 140mmhg systolic, \>90mmhg diastolic) * hypotension (blood pressure \< 90mmhg systolic, \< 60 mmhg diastolic) * current alcohol or drug abuse, alcohol consumption the same day as the study * consumption of coffee 7h before * implanted devices (e.g. pacemaker, pumps) * known sleep-wake disorders * dark skin pigmentation * severe metabolic disease (e.g. diabetes) * pregnancy or lactation * physical handicap effecting the two arms * wound in the wrist region * too large or too small wrist

Keywords: sleep apnea hypersomnia parasomnia
efficacy study of an audio device outside incubator allowing broadcasting maternal voice on stability in preterm infants

Conditions: Premature Infant

Summary: the study aims to evaluate the impact on the preterm infants' short-term physiological, neurodevelopmental states by employing maternal voice intervention in nicu routine care. this study also evaluates the correlation between effective intervention and maternal depression by employing edinburgh postnatal depression scale .

the study designs a two-arm, double blind randomized control trial (rct) experiment in terms of a block randomization for allocating participants in experimental and control groups respectively. in the experimental group maternal voice in terms of lullaby, music, and meaningful words plays near the head of premature infant in the incubator by 30 mins each time, and totally three times a day over a 14-days intervention duration. meanwhile a standard care treats premature infants in the control group. a intellivue physiological monitor and a behavior scale collects ecg, respiratory rate, spo2 concentration, and sleep/awake states of premature infants in both groups. finally, anova analyzes the statistical significance between the measurer and items.

Eligibility criteria:
inclusion criteria: * preterm infants at 28-36 gestational age * within 10 days in nicu after delivery exclusion criteria: 1. has a known chromosomal or congenital abnormality 2. major congenital infection 3. brain lesions diagnosed prenatally, or neonatal asphyxia at birth. 4. toxic use by the mother during pregnancy 5. intraventricular hemorrhage of third degree or more occurred in brain ultrasound examination 6. are using sedative medication 7. premature infants use endotracheal tube respirator or high-frequency respirator 8. preterm infants requiring immediate surgical treatment at birth

Keywords: premature infant
refitting somofilcon a toric contact lens wearers into fanfilcon a toric lenses for 4-weeks of wear

Conditions: Astigmatism

Summary: the aim of this prospective study is to evaluate the clinical performance of habitual wearers of clariti toric lenses after a refit with avaira vitality toric lenses for 1-month of daily wear.

the aim of this prospective study is to evaluate the clinical performance of habitual wearers of clariti toric lenses after a refit with avaira vitality toric lenses for 1-month of daily wear. this is a prospective, subject masked; bilateral, 1-month refit study comparing the fitting characteristics of clariti toric silicone hydrogel lenses, (somofilcon a); against avaira vitality silicone hydrogel toric lenses (fanfilcon a).

Eligibility criteria:
inclusion criteria: * is between 18 and 40 years of age (inclusive) * has had a self-reported visual exam in the last two years * is an adapted soft toric contact lens wearer * has a contact lens spherical prescription between +6.00 to -8.00 (inclusive) * have no less than -0.75d of astigmatism and no more than -2.25 d in both eyes. * can achieve best corrected spectacle distance visual acuity of 20/25 (0.10 logmar) or better in each eye. * can achieve a distance visual acuity of 20/30 (0.18 logmar) or better in each eye with the study contact lenses. * has clear corneas and no active ocular disease * has read, understood and signed the information consent letter. * patient contact lens refraction should fit within the available parameters of the study lenses. * is willing to comply with the wear schedule (at least 5 days per week, \> 8 hours/day assuming there are no contraindications for doing so). * is willing to comply with the visit schedule exclusion criteria: * has a cl prescription outside the range of the available parameters of the study lenses. * has a spectacle cylinder less than -0.75d or more than -2.50 d of cylinder in either eye. * has a history of not achieving comfortable cl wear (5 days per week; \> 8 hours/day) * has contact lens best corrected distance vision worse than 20/25 (0.10 logmar) in either eye. * presence of clinically significant (grade 2-4) anterior segment abnormalities * presence of ocular or systemic disease or need of medications which might interfere with contact lens wear. * slit lamp findings that would contraindicate contact lens wear such as: * pathological dry eye or associated findings * pterygium, pinguecula, or corneal scars within the visual axis * neovascularization \> 0.75 mm in from of the limbus * giant papillary conjunctivitis (gcp) worse than grade 1 * anterior uveitis or iritis (past or present) * seborrheic eczema, seborrheic conjunctivitis * history of corneal ulcers or fungal infections * poor personal hygiene * has a known history of corneal hypoesthesia (reduced corneal sensitivity) * has aphakia, keratoconus or a highly irregular cornea. * has presbyopia or has dependence on spectacles for near work over the contact lenses. * has undergone corneal refractive surgery. * is participating in any other type of eye related clinical or research study.
a urinary tumor marker (kidney injury molecule-1) for the detection of renal cell carcinoma

Conditions: Renal Cell Carcinoma

Summary: the ultimate goal of this project is to develop a simple non-invasive method to screen patients for potential kidney tumors.

in the united states there were 38,900 cases and 12,840 deaths from renal cell carcinoma in 2006. renal cell carcinoma represents 2% of all cancers worldwide. the majority of kidney tumors are discovered incidentally during investigation of unrelated complaints. however, nearly 30% of patients present with metastatic disease at the time of diagnosis and 30-40% of patients with clinically localized kidney cancer will have a recurrence. the diagnosis and monitoring of kidney cancer requires expensive and frequent imaging examinations. there is a significant need to find diagnostic and prognostic biomarkers to screen, diagnose, and monitor renal cancers. a reliable urinary assay for kidney cancer would have major implications for tumor screening in high risk patients, in selection of patients for adjuvant therapy, in surveillance and prognosis and possibly as a surrogate marker for response to therapy. human kidney injury molecule-1 (kim-1) has been found to be a sensitive and specific biomarker in identifying kidney injury. the urine levels of kim-1 are increased in the patients with kidney failure and major types of kidney tumors. the purpose of the study is investigate how urine kim-1 and a routine blood marker for renal failure (creatinine) can distinguish kidney tumors from non-tumor kidney injury. the ultimate goal of this project is to develop a simple non-invasive method to screen patients for potential kidney tumors.

Eligibility criteria:
inclusion criteria: * patients demonstrate normal serum creatinine and no radiological evidence of a renal tumor. or * patients diagnosed with renal cancer and normal creatinine. exclusion criteria: * none.

Keywords: renal cell carcinoma biomarkers
l-arginine in children having sickle cell disease with increased tricuspid regurgitant jet velocity

Conditions: Sickle Cell Disease

Summary: this study aims to investigate the possible efficacy and safety of l-arginine in children having sickle cell disease with increased tricuspid regurgitant jet velocity


Eligibility criteria:
inclusion criteria: * children having sickle cell disease with increased tricuspid regurgitant jet velocity * age 5-18 years exclusion criteria: * another chronic hemolytic anemia. * patients with documented causes of pulmonary hypertension other than scd. * allergy to l-arginine. * patients with asthma. * hepatic dysfunction: serum alanine aminotransferase (alt) \> 3x upper value. * renal dysfunction: creatinine level greater than or equal to 1.2 mg/dl.